225Ac bisPSMA (Clarity Pharmaceuticals)

N/A

Report date: 2025/11/20 16:04:54

Base Information

Drug Name225Ac bisPSMA (Clarity Pharmaceuticals)

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsIonising radiation emitters

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesClarity Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesClarity Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A